{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:10:06Z","timestamp":1780416606241,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106968","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:43:24Z","timestamp":1767339804000},"page":"106968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6417-2680","authenticated-orcid":false,"given":"Megan","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"DeClercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie R.","family":"Cruchelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.106968_bib0001","series-title":"Bafiertam (Package Insert)","year":"2023"},{"key":"10.1016\/j.msard.2026.106968_bib0002","series-title":"Tecfidera (Package Insert)","year":"2023"},{"key":"10.1016\/j.msard.2026.106968_bib0003","series-title":"Vumerity (Package Insert)","year":"2023"},{"key":"10.1016\/j.msard.2026.106968_bib0004","article-title":"Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate","volume":"57","author":"Chu","year":"2022","journal-title":"Mult. Scle Relat. Disord."},{"key":"10.1016\/j.msard.2026.106968_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105737","article-title":"Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate","author":"Dempsey","year":"2024","journal-title":"Mult Scle. Relat .Disord."},{"key":"10.1016\/j.msard.2026.106968_bib0006","series-title":"Lexi-Drugs","year":"2024"},{"key":"10.1016\/j.msard.2026.106968_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.dscb.2025.100229","article-title":"Lymphocyte dynamics in patients with multiple sclerosis who were treated with dimethyl fumarate and subsequently switched to diroximel fumarate","volume":"18","author":"Gales","year":"2025","journal-title":"Brain Disord."},{"issue":"12","key":"10.1016\/j.msard.2026.106968_bib0008","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.106968_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","author":"Harris","year":"2019","journal-title":"J. Biomed. Inf."},{"key":"10.1016\/j.msard.2026.106968_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","author":"Harris","year":"2019","journal-title":"J. Biomed. Inf."},{"issue":"12","key":"10.1016\/j.msard.2026.106968_bib0011","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2026.106968_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1352458520949158","article-title":"Progressive multifocal leukoencephalopathy in dimethyl fumarate treated multiple sclerosis patients","volume":"28","author":"Jordan","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2026.106968_bib0013","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/1352458520937282","article-title":"Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity","volume":"27","author":"Longbrake","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.106968_bib0014","first-page":"1","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","volume":"1","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2026.106968_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00415-019-09557-w","article-title":"Risk factors for lymphopenia in patients with relapsing\u2013remitting multiple sclerosis treated with dimethyl fumarate","volume":"267","author":"Morales","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.106968_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104081","article-title":"Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis","volume":"67","author":"Ravn","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.106968_bib0017","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1177\/13524585241242027","article-title":"New onset lymphopenia in patients with relapsing multiple sclerosis switching from long-standing dimethyl fumarate treatment to diroximel fumarate: a case series","volume":"30","author":"Schneider","year":"2024","journal-title":"Mult. Scle. J."},{"issue":"14","key":"10.1016\/j.msard.2026.106968_bib0018","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1177\/13524585231205708","article-title":"Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase 3 EVOLVE-MS-1 study","volume":"29","author":"Singer","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.106968_bib0019","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","article-title":"Dimethyl fumarate is a potent inducer of apoptosis in human T cells","volume":"121","author":"Treumer","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.msard.2026.106968_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-021-02165-0","article-title":"Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapy decisions","volume":"21","author":"Vola","year":"2021","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.106968_bib0021","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study","volume":"39","author":"Wray","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2026.106968_bib0022","article-title":"Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate","volume":"45","author":"Wynn","year":"2020","journal-title":"Mult. Scle. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:50:41Z","timestamp":1780415441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"alternative-id":["S2211034826000040"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106968","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective review of lymphocyte changes when switching between fumarates in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106968"}}